Bahram Valamehr, Chief R&D Officer at FATE THERAPEUTICS INC (FATE), sold 46,300 shares at $45.68 ($2.2M) on 2021-12-13, disclosed to the SEC on 2021-12-14.
Open-market sale of $2.2M FATE by Chief R&D Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $45.68 | 2,100 | $96K | 4.3% |
| 2 | $46.72 | 7,018 | $328K | 14.8% |
| 3 | $46.72 | 7,018 | $328K | 14.8% |
| 4 | $47.61 | 6,564 | $313K | 14.2% |
| 5 | $47.61 | 6,564 | $313K | 14.2% |
| 6 | $48.75 | 7,718 |
| $376K |
| 17.0% |
| 7 | $48.75 | 7,718 | $376K | 17.0% |
| 8 | $49.27 | 1,600 | $79K | 3.6% |
| Total | $47.69 avg | 46,300 | $2.2M | 100% |
| Filing → |
| FATE | SELL | 2026-01-12 | $6K | — | Filing → |
| FATE | SELL | 2025-08-05 | $15K | — | Filing → |
| FATE | SELL | 2025-01-13 | $13K | — | Filing → |